Organisation: Novo Nordisk AS

Demand for weight-loss drugs highlights key factors for brand owners tackling opportunistic infringers

As Novo Nordisk and Eli Lilly work overtime to meet soaring demand for their popular diabetes and obesity drugs, trademark experts weigh in on what brand owners can do when opportunists take advantage of supply issues.

12 October 2023